What is the significance of a 10-K/A filing?

A 10-K/A filing is an amendment to a company's annual report (Form 10-K). It is filed when a company needs to correct or add material information that was missing or inaccurate in its original 10-K filing. For investors, it's crucial to review the amendments to understand any changes that could impact their investment decisions.

What period does this filing cover?

The filing is for the period ending January 1, 1994, and was filed on June 29, 1994. This typically means it pertains to the company's fiscal year that concluded around the end of 1993.

What specific business segments does Johnson & Johnson typically operate in, and how might they be affected?

Historically, Johnson & Johnson operates across three main segments: Pharmaceuticals, Medical Devices and Diagnostics, and Consumer Health Products. Amendments to their 10-K could provide updated details on the performance, new product developments, or regulatory challenges within any of these key segments.

Where can I find the actual content of the amendments to understand the changes?

To understand the specific changes, you would need to access the full text of the 10-K/A filing from the SEC's EDGAR database. The provided text is only a directory listing and does not contain the report's content. You would typically search for the filing by CIK (Central Index Key) or company name and the specific filing type (10-K/A) and date.

JNJ 10-K FY1994 Annual Report — Revenue, Net Income, EPS

Summary

This filing represents an amendment (10-K/A) to Johnson & Johnson's (JNJ) annual report for the period ending January 1, 1994, filed on June 29, 1994. As an amendment, it likely contains revised or additional information that was not present or was inaccurate in the original filing. Investors should focus on the nature of the amendments to understand any material changes in the company's financial position, operations, or risk factors. Without the specific content of the amendment, it's challenging to provide detailed operational insights. However, the filing date suggests it pertains to the 1993 fiscal year. Investors examining this amendment should look for updates related to revenue streams, profitability, any significant legal or regulatory disclosures, and management's outlook for the company's various segments (likely pharmaceuticals, medical devices, and consumer health products, given JNJ's historical structure).

Key Highlights

1Filing Type: 10-K/A (Annual Report Amendment)
2Company: Johnson & Johnson (JNJ)
3Period End Date: January 1, 1994 (likely representing fiscal year 1993)
4Filing Date: June 29, 1994
5Nature of Filing: Amendment suggests revisions or additions to the original 10-K report.
6Investor Focus: Understanding the reasons and implications of the amendments is key.
7Key Areas to Investigate (if content available): Financial performance, segment-specific results, litigation, regulatory changes, and strategic updates.

JOHNSON & JOHNSON Annual Report (Amendment), Year Ended Jan 2, 1994

Summary

Key Highlights

Frequently Asked Questions